Regulators approve Lilly dog antidepressant

Eli Lilly and Co. said today the Food and Drug Administration has given it the green light to market Lilly’s first product for dogs, an antidepressant called Reconcile.

The drug is the first selective serotonin reuptake inhibitor class of antidepressants approved for canine separation anxiety.

The Indianapolis drugmaker says as many as 10.7 million dogs suffer from separation anxiety.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.